If you are living with secondary progressive multiple sclerosis (SPMS), you know that life feels different from how it used to be. For years, you might have lived in the RRMS world, waiting for an attack, treating it, and mostly … Continue reading → Source:…

The U.S. Food and Drug Administration (FDA) has approved the infusion therapy Ocrevus (ocrelizumab) for treating children with relapsing-remitting multiple sclerosis (RRMS) who are ages 10 and older and weigh at least 55 pounds (25 kg). The approval makes Ocrevus the second-ever therapy to win…